Press Releases
Please, enter cell line, author or any other phrase or word you would like to search for.
PHI Secure Working Capital Until 2023
PHI has received a second loan commitment of 20 MSEK. In total, the company has received loan commitments of 35 MSEK that are expected to secure the company’s working capital until 2023.
PHI granted patent on synthetic antibodies in the U.S.
PHI announces today that the Company has been granted a patent on synthetic antibodies from the United States Patent and Trademark Office.
National Institute on Aging and PHI sign collaboration agreement
The National Institute on Aging and PHI recently entered a collaboration agreement, aiming to develop an add-on fluorescent module for PHI’s HoloMonitor imaging cytometer.
PHI secure working capital until 2022
To bridge and adapt to the consequences of the COVID-19 pandemic, PHI has received a binding credit facility of 15 MSEK.
Gladstone Institutes, University of California and PHI form joint Center of Excellence
Gladstone Institutes, University of California in San Francisco and PHI recently formed San Francisco’s Center of Excellence for Holographic Imaging Cytometry.
New SelectScience eBook helps scientists choose the best cell imaging technology
A new cell imaging technology guide has been launched by leading independent science publisher SelectScience® to help scientists find the best equipment for their applications.
US National Institutes of Health intends to purchase HoloMonitor
The US National Institute of Aging intends to purchase a HoloMonitor instrument from Phase Holographic Imaging. The National Institute of Aging is part of the National Institutes of Health (NIH), a government agency to promote medical research.
Minor insider divestment
PHI Board member Jan Richardsson recently divested 5 328 shares in the company. “The reason for the sale is that I needed to balance an option loss linked to a previous employment”, comments Richardsson.
Correction regarding the publication date of coming interim report
PHI receives 18 MSEK through share options
On June 13, 2019, the exercise period of the TO 2 share options in Phase Holographic Imaging (“PHI”) ended. 632 520 (97.6 %) of the 648 338 outstanding options were exercised. PHI will thus receive approx. 17.8 MSEK before issuing expenses, which are expected to amount to approx. 0.8 MSEK.